[Skip to Content]
[Skip to Content Landing]
Invited Commentary
December 2015

Value-Based Cancer Care and the Excessive Cost of Drugs

Author Affiliations
  • 1USF Health Program for Comparative Effectiveness Research, Division for Evidence-Based Medicine, Department of Internal Medicine, University of South Florida, Tampa
  • 2Departments of Hematology and Health Outcome Behavior, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
  • 3Tampa General Hospital, Tampa, Florida
JAMA Oncol. 2015;1(9):1301-1302. doi:10.1001/jamaoncol.2015.3302

On March 19, 2015, the US Congress repealed the Sustainable Growth Rate Formula as the mechanism to control Medicare spending on physician services and introduced a new merit-based payment system aiming to link financing of health care with performance and “value.” Although the law focuses on the value-based purchasing of existing health services, it inevitably raises the issue of what is the acceptable value as a basis for allowing health services to be introduced in practice. (Regulatory agencies such as the US Food and Drug Administration [FDA] have typically not been concerned about value.)